Replacing Dopamine Neurons in Parkinson's Disease: How did it happen?
Replacing Dopamine Neurons in Parkinson's Disease: How did it happen?
复制标题
DOI：
10.3233/jpd-179002
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Lindvall O
中科院分区：
文献类型：
--
作者：
Björklund A;Lindvall O
开发用于帕金森病的多巴胺细胞替代疗法的努力已经跨越了三十多年。基于近10年的动物模型移植研究，1987年在隆德对第一批接受胎儿来源的多巴胺神经母细胞移植的患者进行了手术。在接下来的二十年里，共有18名患者接受了移植，我们的团队密切关注，结果喜忧参半，但也非常令人鼓舞。在这篇文章中，我们讲述了如何在隆德临床前和临床移植计划的演变。我们还记得，当我们首次获得移植神经元在患病人脑中存活和发挥功能的证据时，我们是多么兴奋。我们还记得我们在这30年中经历的挫折，并讨论这一令人兴奋的领域目前正在发生的非常有趣的发展。
The efforts to develop a dopamine cell replacement therapy for Parkinson’s disease have spanned over more than three decades. Based on almost 10 years of transplantation studies in animal models, the first patients receiving grafts of fetal-derived dopamine neuroblasts were operated in Lund in 1987. Over the following two decades, a total of 18 patients were transplanted and followed closely by our team with mixed but also very encouraging results. In this article we tell the story of how the preclinical and clinical transplantation program in Lund evolved. We recall the excitement when we obtained the first evidence for survival and function of transplanted neurons in the diseased human brain. We also remember the setbacks that we have experienced during these 30 years and discuss the very interesting developments that are now taking place in this exciting field.